Elgia Therapeutics, a venture-backed biopharmaceutical company, is positioned to deliver first-in-class and best-in-class therapies for serious chronic diseases, such as fibrosis, neuroinflammation, NASH, kidney disease, and inflammatory bowel disease (IBD). The Elgia team has discovered how metabolic stress drives inflammation and fibrosis and has identified untapped protein targets for small molecule drug discovery. By combining these pioneering biological insights with R&D expertise, Elgia is creating innovative medicines for debilitating chronic diseases.